| Title |
|
Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis |
|
|
| Publication Date |
|
| Author(s) |
|
| Type of document |
|
| Language |
|
| Entity Type |
|
| Publisher |
|
Korean Association for the Study of Intestinal Diseases,Daehan Jang Yeon'gu Haghoe |
|
|
| Place of publication |
|
| DOI |
|
| UNE publication id |
|
| Abstract |
Ulcerative colitis (UC) is a chronic relapsing remitting inflammatory disease of the colon. The lifetime risk of presentation with acute severe ulcerative colitis (ASUC) is 15%.1 Patients with ASUC receive first line therapy with intravenous corticosteroids, however, approximately 30% have corticosteroid-refractory disease.2,3 In this situation, rescue medical therapy options include the anti-tumor necrosis factor (TNF) monoclonal antibody infliximab (IFX) or the calcineurin inhibitor ciclosporin.2 A significant proportion of patients fail to respond to IFX therapy with reported colectomy rates at 1 year of 35%.4 Biomarkers which identify patients with corticosteroid-refractory ASUC, with a reduced likelihood of IFX response, would significantly advance clinical care for these patients. |
|
|
| Link |
|
| Citation |
|
Intestinal Research, 20(3), p. 381-385 |
|
|
| ISSN |
|
| Start page |
|
| End page |
|
| Rights |
|
Attribution-NonCommercial 4.0 International |
|
|